Brief: Gensight Biologics Updates On Data From Lumevoq Gene Therapy Programs

Gensight Biologics SA

06/03/2024 06:33

March 6 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * ANNOUNCES UPDATE ON REAL-WORLD DATA FROM EARLY ACCESS
PROGRAMS
OF LUMEVOQ® GENE THERAPY AT NANOS 2024
    * CLINICALLY MEANINGFUL IMPROVEMENT IN VISUAL ACUITY
CONFIRMED IN
A REAL-WORLD SETTING: ON-CHART MEAN VISUAL ACUITY AT 9 MONTHS
AFTER INJECTION, COMPARED TO OFF-CHART MEAN AT BASELINE

Source text for Eikon:  ID:nBw4xfbKHa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))